{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:13:43Z","timestamp":1793726023958,"version":"4.6.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biomed Eng"],"DOI":"10.1038\/s41551-021-00797-8","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T12:03:25Z","timestamp":1632744205000},"page":"1288-1305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9652-1120","authenticated-orcid":false,"given":"Bo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezhong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeshuang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7347-9652","authenticated-orcid":false,"given":"Pengchong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3398-5921","authenticated-orcid":false,"given":"Wenxiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyun","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9589-2360","authenticated-orcid":false,"given":"George C.","family":"Tsokos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0339-0959","authenticated-orcid":false,"given":"Demin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8775-1699","authenticated-orcid":false,"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"797_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri3823","volume":"15","author":"D Klatzmann","year":"2015","unstructured":"Klatzmann, D. & Abbas, A. K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. 15, 283\u2013294 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"797_CR2","doi-asserted-by":"publisher","unstructured":"Abbas, A. K., Trotta, E., Simeonov, R. D., Marson, A. & Bluestone, J. A. Revisiting IL-2: biology and therapeutic prospects. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aat1482 (2018).","DOI":"10.1126\/sciimmunol.aat1482"},{"key":"797_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180\u2013190 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"797_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He, J. et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 79, 141\u2013149 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"797_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","volume":"78","author":"M Rosenzwajg","year":"2019","unstructured":"Rosenzwajg, M. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann. Rheum. Dis. 78, 209\u2013217 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"797_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11926-016-0617-5","volume":"18","author":"M Mizui","year":"2016","unstructured":"Mizui, M. & Tsokos, G. C. Low-dose IL-2 in the treatment of lupus. Curr. Rheumatol. Rep. 18, 68 (2016).","journal-title":"Curr. Rheumatol. Rep."},{"key":"797_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cyto.2015.11.020","volume":"78","author":"N Kim","year":"2016","unstructured":"Kim, N. et al. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells. Cytokine 78, 22\u201326 (2016).","journal-title":"Cytokine"},{"key":"797_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nm.4148","volume":"22","author":"J He","year":"2016","unstructured":"He, J. et al. Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nat. Med. 22, 991\u2013993 (2016).","journal-title":"Nat. Med."},{"key":"797_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11892-016-0739-1","volume":"16","author":"CJ Dwyer","year":"2016","unstructured":"Dwyer, C. J., Ward, N. C., Pugliese, A. & Malek, T. R. Promoting immune regulation in type 1 diabetes using low-dose interleukin-2. Curr. Diab. Rep. 16, 46 (2016).","journal-title":"Curr. Diab. Rep."},{"key":"797_CR10","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth, J. et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365, 2055\u20132066 (2011).","journal-title":"N. Engl. J. Med."},{"key":"797_CR11","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","volume":"365","author":"D Saadoun","year":"2011","unstructured":"Saadoun, D. et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365, 2067\u20132077 (2011).","journal-title":"N. Engl. J. Med."},{"key":"797_CR12","doi-asserted-by":"publisher","unstructured":"Pol, J. G., Caudana, P., Paillet, J., Piaggio, E. & Kroemer, G. Effects of interleukin-2 in immunostimulation and immunosuppression. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20191247 (2020).","DOI":"10.1084\/jem.20191247"},{"key":"797_CR13","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.4049\/jimmunol.135.4.2865","volume":"135","author":"MT Lotze","year":"1985","unstructured":"Lotze, M. T. et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. 135, 2865\u20132875 (1985).","journal-title":"J. Immunol."},{"key":"797_CR14","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1126\/science.1122927","volume":"311","author":"O Boyman","year":"2006","unstructured":"Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. & Sprent, J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924\u20131927 (2006).","journal-title":"Science"},{"key":"797_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10975","volume":"484","author":"AM Levin","year":"2012","unstructured":"Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine\u2019. Nature 484, 529\u2013533 (2012).","journal-title":"Nature"},{"key":"797_CR16","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.immuni.2015.04.018","volume":"42","author":"S Mitra","year":"2015","unstructured":"Mitra, S. et al. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity 42, 826\u2013838 (2015).","journal-title":"Immunity"},{"key":"797_CR17","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.4049\/jimmunol.1800907","volume":"201","author":"NC Ward","year":"2018","unstructured":"Ward, N. C. et al. IL-2\/CD25: a long-acting fusion protein that promotes immune tolerance by selectively targeting the IL-2 receptor on regulatory T cells. J. Immunol. 201, 2579\u20132592 (2018).","journal-title":"J. Immunol."},{"key":"797_CR18","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1126\/science.aar3246","volume":"359","author":"JT Sockolosky","year":"2018","unstructured":"Sockolosky, J. T. et al. Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. Science 359, 1037\u20131042 (2018).","journal-title":"Science"},{"key":"797_CR19","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.4049\/jimmunol.1800578","volume":"201","author":"JB Spangler","year":"2018","unstructured":"Spangler, J. B. et al. Engineering a single-agent cytokine\/antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy. J. Immunol. 201, 2094\u20132106 (2018).","journal-title":"J. Immunol."},{"key":"797_CR20","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41591-018-0070-2","volume":"24","author":"E Trotta","year":"2018","unstructured":"Trotta, E. et al. A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. Nat. Med. 24, 1005\u20131014 (2018).","journal-title":"Nat. Med."},{"key":"797_CR21","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/protein\/gzg111","volume":"16","author":"BM Rao","year":"2003","unstructured":"Rao, B. M., Girvin, A. T., Ciardelli, T., Lauffenburger, D. A. & Wittrup, K. D. Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity. Protein Eng. 16, 1081\u20131087 (2003).","journal-title":"Protein Eng."},{"key":"797_CR22","doi-asserted-by":"publisher","first-page":"6230","DOI":"10.4049\/jimmunol.1201895","volume":"190","author":"T Carmenate","year":"2013","unstructured":"Carmenate, T. et al. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J. Immunol. 190, 6230\u20136238 (2013).","journal-title":"J. Immunol."},{"key":"797_CR23","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/CJI.0b013e3181b528da","volume":"32","author":"DV Liu","year":"2009","unstructured":"Liu, D. V., Maier, L. M., Hafler, D. A. & Wittrup, K. D. Engineered interleukin-2 antagonists for the inhibition of regulatory T cells. J. Immunother. 32, 887\u2013894 (2009).","journal-title":"J. Immunother."},{"key":"797_CR24","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.4049\/jimmunol.1700433","volume":"200","author":"T Carmenate","year":"2018","unstructured":"Carmenate, T. et al. Blocking IL-2 signal in vivo with an IL-2 antagonist reduces tumor growth through the control of regulatory T cells. J. Immunol. 200, 3475\u20133484 (2018).","journal-title":"J. Immunol."},{"key":"797_CR25","doi-asserted-by":"publisher","unstructured":"Karakus, U. et al. Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abb9283 (2020).","DOI":"10.1126\/scitranslmed.abb9283"},{"key":"797_CR26","doi-asserted-by":"publisher","first-page":"1681869","DOI":"10.1080\/2162402X.2019.1681869","volume":"9","author":"JY Lee","year":"2020","unstructured":"Lee, J. Y. et al. TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity. Oncoimmunology 9, 1681869 (2020).","journal-title":"Oncoimmunology"},{"key":"797_CR27","doi-asserted-by":"publisher","first-page":"367ra166","DOI":"10.1126\/scitranslmed.aag3187","volume":"8","author":"N Arenas-Ramirez","year":"2016","unstructured":"Arenas-Ramirez, N. et al. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Sci. Transl. Med. 8, 367ra166 (2016).","journal-title":"Sci. Transl. Med."},{"key":"797_CR28","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.immuni.2015.04.015","volume":"42","author":"JB Spangler","year":"2015","unstructured":"Spangler, J. B. et al. Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms. Immunity 42, 815\u2013825 (2015).","journal-title":"Immunity"},{"key":"797_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20220-1","volume":"11","author":"D Sahin","year":"2020","unstructured":"Sahin, D. et al. An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer. Nat. Commun. 11, 6440 (2020).","journal-title":"Nat. Commun."},{"key":"797_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.10.017","volume":"95","author":"LB Peterson","year":"2018","unstructured":"Peterson, L. B. et al. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. J. Autoimmun. 95, 1\u201314 (2018).","journal-title":"J. Autoimmun."},{"key":"797_CR31","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jconrel.2011.10.037","volume":"161","author":"G Pasut","year":"2012","unstructured":"Pasut, G. & Veronese, F. M. State of the art in PEGylation: the great versatility achieved after forty years of research. J. Control. Release 161, 461\u2013472 (2012).","journal-title":"J. Control. Release"},{"key":"797_CR32","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","volume":"22","author":"DH Charych","year":"2016","unstructured":"Charych, D. H. et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin. Cancer Res. 22, 680\u2013690 (2016).","journal-title":"Clin. Cancer Res."},{"key":"797_CR33","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1073\/pnas.1321237111","volume":"111","author":"F Tian","year":"2014","unstructured":"Tian, F. et al. A general approach to site-specific antibody drug conjugates. Proc. Natl Acad. Sci. USA 111, 1766\u20131771 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"797_CR34","doi-asserted-by":"publisher","first-page":"9060","DOI":"10.1073\/pnas.1100387108","volume":"108","author":"H Cho","year":"2011","unstructured":"Cho, H. et al. Optimized clinical performance of growth hormone with an expanded genetic code. Proc. Natl Acad. Sci. USA 108, 9060\u20139065 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"797_CR35","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.actbio.2015.03.002","volume":"19","author":"B Zhang","year":"2015","unstructured":"Zhang, B. et al. Development of next generation of therapeutic IFN-\u03b12b via genetic code expansion. Acta Biomater. 19, 100\u2013111 (2015).","journal-title":"Acta Biomater."},{"key":"797_CR36","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2017.01.029","volume":"249","author":"L Wu","year":"2017","unstructured":"Wu, L. et al. Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone. J. Control. Release 249, 84\u201393 (2017).","journal-title":"J. Control. Release"},{"key":"797_CR37","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1002\/cbic.201100117","volume":"12","author":"NE Mbua","year":"2011","unstructured":"Mbua, N. E., Guo, J., Wolfert, M. A., Steet, R. & Boons, G. J. Strain-promoted alkyne-azide cycloadditions (SPAAC) reveal new features of glycoconjugate biosynthesis. ChemBioChem 12, 1912\u20131921 (2011).","journal-title":"ChemBioChem"},{"key":"797_CR38","doi-asserted-by":"publisher","first-page":"8720","DOI":"10.1021\/ja900553w","volume":"131","author":"DP Nguyen","year":"2009","unstructured":"Nguyen, D. P. et al. Genetic encoding and labeling of aliphatic azides and alkynes in recombinant proteins via a pyrrolysyl-tRNA synthetase\/tRNACUA pair and click chemistry. J. Am. Chem. Soc. 131, 8720\u20138721 (2009).","journal-title":"J. Am. Chem. Soc."},{"key":"797_CR39","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1073\/pnas.0511161103","volume":"103","author":"DJ Stauber","year":"2006","unstructured":"Stauber, D. J., Debler, E. W., Horton, P. A., Smith, K. A. & Wilson, I. A. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc. Natl Acad. Sci. USA 103, 2788\u20132793 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"797_CR40","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1126\/science.1117893","volume":"310","author":"X Wang","year":"2005","unstructured":"Wang, X., Rickert, M. & Garcia, K. C. Structure of the quaternary complex of interleukin-2 with its \u03b1, \u03b2, and \u03b3c receptors. Science 310, 1159\u20131163 (2005).","journal-title":"Science"},{"key":"797_CR41","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.2337\/db14-1322","volume":"64","author":"A Yu","year":"2015","unstructured":"Yu, A. et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes 64, 2172\u20132183 (2015).","journal-title":"Diabetes"},{"key":"797_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jim.2008.11.019","volume":"342","author":"M Miksa","year":"2009","unstructured":"Miksa, M., Komura, H., Wu, R., Shah, K. G. & Wang, P. A novel method to determine the engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester. J. Immunol. Methods 342, 71\u201377 (2009).","journal-title":"J. Immunol. Methods"},{"key":"797_CR43","doi-asserted-by":"publisher","first-page":"10696","DOI":"10.1021\/bi050436x","volume":"44","author":"BM Rao","year":"2005","unstructured":"Rao, B. M., Driver, I., Lauffenburger, D. A. & Wittrup, K. D. High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth. Biochemistry 44, 10696\u201310701 (2005).","journal-title":"Biochemistry"},{"key":"797_CR44","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","volume":"19","author":"M Dominguez-Villar","year":"2018","unstructured":"Dominguez-Villar, M. & Hafler, D. A. Regulatory T cells in autoimmune disease. Nat. Immunol. 19, 665\u2013673 (2018).","journal-title":"Nat. Immunol."},{"key":"797_CR45","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nprot.2007.173","volume":"2","author":"DD Brand","year":"2007","unstructured":"Brand, D. D., Latham, K. A. & Rosloniec, E. F. Collagen-induced arthritis. Nat. Protoc. 2, 1269\u20131275 (2007).","journal-title":"Nat. Protoc."},{"key":"797_CR46","doi-asserted-by":"publisher","first-page":"11906","DOI":"10.1073\/pnas.1002569107","volume":"107","author":"C Krieg","year":"2010","unstructured":"Krieg, C., Letourneau, S., Pantaleo, G. & Boyman, O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl Acad. Sci. USA 107, 11906\u201311911 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"797_CR47","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.immuni.2008.03.018","volume":"28","author":"T Ito","year":"2008","unstructured":"Ito, T. et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 28, 870\u2013880 (2008).","journal-title":"Immunity"},{"key":"797_CR48","first-page":"119","volume":"286","author":"F Gesbert","year":"2004","unstructured":"Gesbert, F., Sauvonnet, N. & Dautry-Varsat, A. Clathrin-independent endocytosis and signalling of interleukin 2 receptors IL-2R endocytosis and signalling. Curr. Top. Microbiol. Immunol. 286, 119\u2013148 (2004).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"797_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01570-9","volume":"8","author":"Y Li","year":"2017","unstructured":"Li, Y. et al. Regulatory T cells control toxicity in a humanized model of IL-2 therapy. Nat. Commun. 8, 1762 (2017).","journal-title":"Nat. Commun."},{"key":"797_CR50","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.immuni.2017.03.013","volume":"46","author":"F Arce Vargas","year":"2017","unstructured":"Arce Vargas, F. et al. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity 46, 577\u2013586 (2017).","journal-title":"Immunity"},{"key":"797_CR51","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","volume":"9","author":"K Hofmann","year":"2018","unstructured":"Hofmann, K., Clauder, A. K. & Manz, R. A. Targeting B cells and plasma cells in autoimmune diseases. Front. Immunol. 9, 835 (2018).","journal-title":"Front. Immunol."},{"key":"797_CR52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.clim.2018.11.002","volume":"206","author":"M Mizui","year":"2019","unstructured":"Mizui, M. Natural and modified IL-2 for the treatment of cancer and autoimmune diseases. Clin. Immunol. 206, 63\u201370 (2019).","journal-title":"Clin. Immunol."},{"key":"797_CR53","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.drudis.2014.08.015","volume":"19","author":"JJ Verhoef","year":"2014","unstructured":"Verhoef, J. J., Carpenter, J. F., Anchordoquy, T. J. & Schellekens, H. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov. Today 19, 1945\u20131952 (2014).","journal-title":"Drug Discov. Today"},{"key":"797_CR54","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","volume":"9","author":"RP Garay","year":"2012","unstructured":"Garay, R. P., El-Gewely, R., Armstrong, J. K., Garratty, G. & Richette, P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin. Drug Deliv. 9, 1319\u20131323 (2012).","journal-title":"Expert Opin. Drug Deliv."},{"key":"797_CR55","doi-asserted-by":"publisher","first-page":"R24","DOI":"10.1186\/ar1879","volume":"8","author":"X Tao","year":"2006","unstructured":"Tao, X., Fan, F., Hoffmann, V., Longo, N. S. & Lipsky, P. E. Therapeutic impact of the ethyl acetate extract of Tripterygium wilfordii Hook F on nephritis in NZB\/W F1 mice. Arthritis Res. Ther. 8, R24 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"797_CR56","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/89782","volume":"2","author":"H Wang","year":"2001","unstructured":"Wang, H. et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat. Immunol. 2, 632\u2013637 (2001).","journal-title":"Nat. Immunol."},{"key":"797_CR57","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/nm1304","volume":"11","author":"GM Deng","year":"2005","unstructured":"Deng, G. M., Zheng, L., Chan, F. K. & Lenardo, M. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat. Med. 11, 1066\u20131072 (2005).","journal-title":"Nat. Med."},{"key":"797_CR58","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.4049\/jimmunol.1303303","volume":"193","author":"J Wang","year":"2014","unstructured":"Wang, J. et al. Klebsiella pneumoniae alleviates influenza-induced acute lung injury via limiting NK cell expansion. J. Immunol. 193, 1133\u20131141 (2014).","journal-title":"J. Immunol."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-021-00797-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-021-00797-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-021-00797-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:11:49Z","timestamp":1733937109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-021-00797-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":58,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1038\/s41551-021-00797-8","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"assertion":[{"value":"8 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}